Introduction
BDFUCIL is a combination anticancer medication that includes tegafur and uracil. This oral therapy is designed to deliver a more tolerable and sustained form of fluorouracil activity, commonly used in the treatment of various solid tumors. By combining a prodrug of fluorouracil with a modulator that enhances its effect and reduces breakdown, BDFUCIL provides effective cancer control with improved convenience and reduced toxicity compared to conventional intravenous regimens.

Mechanism of Action
Tegafur is a prodrug that slowly converts into fluorouracil in the body, a well-established chemotherapy agent that disrupts DNA and RNA synthesis in rapidly dividing cancer cells. Uracil works by competitively inhibiting the enzyme dihydropyrimidine dehydrogenase, which normally breaks down fluorouracil. This inhibition allows fluorouracil levels to remain higher for longer periods, enhancing its anticancer effect while reducing the need for high doses and limiting toxicity. Together, the combination targets tumor cells more efficiently and maintains therapeutic levels of the active drug.

Uses
BDFUCIL is used in the treatment of various cancers, including colorectal, gastric, pancreatic, and breast cancer. It may be administered alone or in combination with other chemotherapy agents as part of a broader treatment protocol. Its oral formulation makes it especially valuable in outpatient care settings and for patients requiring long-term therapy.

Adverse Effects
Common side effects may include fatigue, nausea, mild gastrointestinal discomfort, and appetite changes. Some patients may experience hand-foot syndrome, diarrhea, or mucositis. Blood-related side effects like low white blood cell or platelet counts can occur and should be monitored regularly. Rare but serious effects may include liver dysfunction and signs of cardiotoxicity. Supportive care and routine monitoring are essential to manage and minimise potential complications during treatment.